Anderström C, Eddeland A, Folmerz P, Hansson R, Milles S, Zachrisson B
Department of Urology, Kärnsjukhuset, Skövde, Sweden.
Eur Urol. 1995;27(4):301-5. doi: 10.1159/000475185.
The effect of a medroxyprogesterone acetate (MPA) plus epirubicin combination versus estramustine phosphate was evaluated in 149 prospectively randomized patients with hormone-resistant prostatic cancer. The estimated probability of being free from progression after 1 year was 17% for the patients treated with estramustine and 29% for the MPA-epirubicin group. There is a significant difference between the two groups regarding risk of progression (p = 0.013). However, no difference in survival was recorded (p > 0.30) with about 60% of the patients dead during the first year in both groups. Progression was highly correlated to sedimentation rate (p < 0.001) and to performance index (p = 0.002). Heart failure occurred in a substantial number of patients in both groups which must be considered before starting therapy.
对149例激素抵抗性前列腺癌患者进行前瞻性随机分组，评估醋酸甲羟孕酮（MPA）联合表柔比星与磷酸雌莫司汀的疗效。接受磷酸雌莫司汀治疗的患者1年后无进展的估计概率为17%，MPA-表柔比星组为29%。两组在进展风险方面存在显著差异（p = 0.013）。然而，未记录到生存差异（p > 0.30），两组中约60%的患者在第一年死亡。进展与血沉率（p < 0.001）和体能指数（p = 0.002）高度相关。两组均有相当数量的患者发生心力衰竭，在开始治疗前必须予以考虑。
